Clinical trials: multiple sclerosis
Multiple Sclerosis, Clinically Isolated Syndrome of Demyelination
Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)
Multiple Sclerosis (MS) is a chronic inflammatory \& degenerative disease of the central nervous system (CNS) Recent data from the MS Base registry demonstrated an average delay of 152 - 215 days between first presentation and…
- Trial name
- AttackMS (NCT05418010)
- Testing
- Tyruko Injectable Product
- Where
- 2 sites in United Kingdom
- Volunteers
- 40 people
- Sponsor
- Queen Mary University of London
Multiple Sclerosis
Obesity and Pediatric Multiple Sclerosis
Obesity is one possible contributor to severity of multiple sclerosis and progression of the disease. We already know that obesity is a risk determinant for acquiring MS, yet the impact of obesity on pediatric MS disease…
- Trial name
- NCT04593082
- Where
- 2 sites in United States
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- University of Virginia
Multiple Sclerosis
Safety and Neuroprotective Effects of Polyphenon E in MS; Phase II
The hypothesis is that Polyphenon E can protect brain cells in patients with Multiple Sclerosis. To test this hypothesis we are going to compare the changes in n-Acetyl-Aspartate (a chemical that reflects the number of neurons…
- Trial name
- POEMS (NCT01451723)
- Testing
- Polyphenon E
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Louisiana State University Health Sciences Center in New Orleans
Multiple Sclerosis, Clinically Isolated Syndrome
Assessing the Feasibility of the MSPT Device in Routine Clinical Practice in the Swiss Healthcare System
The Multiple Sclerosis Functional Composite (MSFC), a reliable and well-validated instrument, was developed as a multidimensional quantitative measure of neurologic disability in MS.
- Trial name
- MSPT (NCT04599023)
- Testing
- MSPT
- Where
- Switzerland
- Volunteers
- 182 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Headache, Migraine
RELAXaHEAD for Headache Patients (Phase I)
The goal of this research is to assess the utility of smartphone-based progressive muscle relaxation (PMR) for the treatment of headaches.
- Conditions
- Headache, Migraine, Multiple Sclerosis
- Trial name
- NCT03183791
- Testing
- RELAXaHEAD app, Monitored Usual Care (MUC)
- Where
- United States
- Volunteers
- 402 people
- Sponsor
- NYU Langone Health
Multiple Sclerosis, Vocational Rehabilitation
Feasibility of a Vocational Rehabilitation Intervention for Job Retention in Workers With MS-RiaLSM Intervention Project
Multiple sclerosis (MS) is an autoimmune demyelinating disease of the central nervous system with both inflammatory and degenerative characteristics that affects approximately 136,000 people in Italy.
- Trial name
- RialSM (NCT06805318)
- Testing
- Vocational Rehabilitation intervention for pwMS
- Where
- 2 sites in Italy
- Volunteers
- 30 people
- Sponsor
- Fondazione Italiana Sclerosi Multipla
Multiple Sclerosis
Efficacy of tDCS on Pain in Multiple Sclerosis
Pain is a common symptom experienced by people with MS and can significantly interfere with participation in the activities of daily living and adversely affect health-related quality of life.
- Trial name
- NCT03389217
- Testing
- Real-tDCS + rehabilitation programme
- Where
- Italy
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University Hospital of Ferrara
Multiple Sclerosis, Optic Neuritis
Neuroprotection and Repair in Optic Neuritis
The primary aim of this open-label pilot trial is to estimate the treatment effect of 100 mg of oral minocycline twice daily for 90 days, initiated within 30 days of onset of ON, on functional and structural optic nerve recovery…
- Trial name
- Mino in ON (NCT01073813)
- Testing
- Minocycline
- Volunteers
- 6 people
- Sponsor
- University of Calgary
Spasticity Due to Multiple Sclerosis
BX-1 in Spasticity Due to Multiple Sclerosis
To investigate the efficacy and safety of orally administered BX-1 compared to placebo in patients with spasticity due to multiple sclerosis not sufficiently controlled by current anti-spasticity medication
- Trial name
- NCT03756974
- Testing
- BX-1
- Where
- 40 sites in Czechia, Germany and 3 more
- Volunteers
- 397 people
- Sponsor
- Bionorica SE
Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Metformin Treatment in Progressive Multiple Sclerosis
The purpose of this study is to assess the safety of metformin for treatment of progressive multiple sclerosis
- Trial name
- NCT05349474
- Testing
- Metformin 500 Mg Oral Tablet, up to 4 tablets a day
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of California, Los Angeles
Multiple Sclerosis
Validation of a Smartwatch in Persons With Multiple Sclerosis
The study is designed to validate the accuracy of steps detected by a commercially available smartwatch in persons with multiple sclerosis.
- Trial name
- NCT03750097
- Testing
- Comfortable walking velocity (CWV), Slow walking velocity (SWV: CWV - 20%), Fast walking velocity (FWV: CWV + 20%)
- Where
- Germany
- Volunteers
- 58 people
- Sponsor
- University of Erlangen-Nürnberg
Multiple Sclerosis, Mood Disorders
Study of Brain Activations and Physiological Responses Using NeuroBiofeedback in Patients With Multiple Sclerosis
Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS) characterized by inflammation, demyelination, gliosis, and neuronal loss.
- Conditions
- Multiple Sclerosis, Mood Disorders, Cognitive Impairment
- Trial name
- NBF2023 (NCT06239090)
- Testing
- Rehacor-T
- Where
- Italy
- Volunteers
- 44 people
- Sponsor
- IRCCS Centro Neurolesi Bonino Pulejo
Multiple Sclerosis
Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
Background: In people with multiple sclerosis (MS), brain and cerebrospinal fluid (CSF) biomarkers indicate inflammation or disease. Researchers want to see if 4 drugs given alone or combined affect MS biomarkers.
- Trial name
- NCT03109288
- Testing
- Cilostazol, Leucovorin, Pirfenidone
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Multiple Sclerosis
Novel Immune Markers in Patients With Multiple Sclerosis
The investigators hypothesize that the endogenous cannabinoid signalling system has lost homeostasis in the disease multiple sclerosis (MS).
- Trial name
- NIMMS (NCT01026272)
- Where
- 2 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Washington
Multiple Sclerosis
Validation of the 18 kiloDalton Translocator Protein (TSPO) as a Novel Neuroimmunodulatory Target
In multiple sclerosis (MS) cells of the immune system attack the brain causing tissue damage. In secondary progressive MS (SPMS) these repeated immune attacks have stopped but despite this new damage continues to appear.
- Trial name
- TSPO (NCT03850301)
- Testing
- XBD173, Etifoxine
- Where
- United Kingdom
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Tuberous Sclerosis Complex
Predicting Epileptogenic Tubers in Patients with Tuberous Sclerosis Complex
Accurate localization of epileptogenic tubers (ETs) in patients with tuberous sclerosis complex (TSC) is essential but challenging because ETs lack distinct pathological or genetic markers that differentiate them from other…
- Trial name
- NCT06789419
- Volunteers
- 112 people
- Sponsor
- Beijing Children's Hospital
Multiple Sclerosis
Effectiveness of the EXOPULSE Mollii Ⓡ Suit in Patients With Multiple Sclerosis
Abstract: Background: Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system with unknown etiology, causing a variety of symptoms including impaired balance, coordination, and…
- Trial name
- NCT06384729
- Testing
- EXOPULSE Mollii Ⓡ
- Where
- Spain
- Volunteers
- 12 people
- Sponsor
- Universidad Europea de Madrid
Pediatric Multiple Sclerosis
Mobile Attentional Bias Modification Training in Pediatric MS
This study will examine the feasibility of using a mobile ABMT application as a treatment modality in the Pediatric Multiple Sclerosis population.
- Trial name
- NCT04441229
- Testing
- ABMT mobile application
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- NYU Langone Health
Multiple Sclerosis
Task Specific Training for Advanced Multiple Sclerosis
The purpose of this study is to find effective physical therapy treatments for individuals who have severe multiple sclerosis. Physical therapy treatments for mild-to-moderate multiple sclerosis exists, however, very limited…
- Trial name
- NCT06506929
- Testing
- Task specific physical therapy
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Hunter College of City University of New York
Multiple Sclerosis
Efficacy of PoNS in Reducing Symptoms of Multiple Sclerosis
The purpose of this pilot study is to determine whether a program involving both in-lab and at-home training using cranial nerve stimulation (CN-NINM) delivered via the tongue can reduce symptoms of multiple sclerosis (MS) and…
- Trial name
- NCT04496531
- Testing
- Portable Neuromodulation Stimulator
- Volunteers
- 14 people
- Sponsor
- Helius Medical Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.